
ESTA Stock Forecast & Price Target
ESTA Analyst Ratings
Bulls say
Establishment Labs Holdings Inc has demonstrated a significant improvement in its financial performance, highlighted by an increase in EBITDA margin both sequentially and year-over-year, with gross margins reaching 70.1%, exceeding industry consensus. The company's successful launch of the Motiva product line has invigorated the breast aesthetics market, leading to a reported 15% year-over-year increase in procedure volumes for practices that adopted Motiva. Furthermore, Establishment Labs expects to finish 2026 with a notable increase in cash reserves, forecasting $75.5 million, up from $71 million in the previous year, indicating strong financial positioning and growth potential.
Bears say
Establishment Labs Holdings Inc. is facing a negative outlook due to anticipated revenue growth falling below 20%, attributed to weaker-than-expected sales in the U.S. market and a slower trajectory toward profitability. Additionally, international growth has shown significant deceleration, with projections indicating minimal growth—approximately 2%—for both 2024 and 2025. The company is also confronted with several risks, including disappointing U.S. sales, potential economic downturns affecting international demand, and uncertainties surrounding real-world complication rates related to its products.
This aggregate rating is based on analysts' research of Establishment Labs Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ESTA Analyst Forecast & Price Prediction
Start investing in ESTA
Order type
Buy in
Order amount
Est. shares
0 shares